Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TerrAscend (TSNDF) Cash & Equivalents (2021 - 2025)

TerrAscend (TSNDF) has disclosed Cash & Equivalents for 5 consecutive years, with $110000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 81.85% to $110000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $110000.0, a 81.85% decrease, with the full-year FY2024 number at $26.4 million, up 18.61% from a year prior.
  • Cash & Equivalents was $110000.0 for Q3 2025 at TerrAscend, down from $26.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $88.4 million in Q1 2022 to a low of $110000.0 in Q3 2025.
  • A 5-year average of $27.2 million and a median of $25.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 99.31% in 2023, then skyrocketed 3639.93% in 2024.
  • TerrAscend's Cash & Equivalents stood at $79.6 million in 2021, then plummeted by 99.24% to $605000.0 in 2022, then skyrocketed by 3576.2% to $22.2 million in 2023, then grew by 18.61% to $26.4 million in 2024, then plummeted by 99.58% to $110000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSNDF's Cash & Equivalents are $110000.0 (Q3 2025), $26.7 million (Q2 2025), and $29.2 million (Q1 2025).